165 related articles for article (PubMed ID: 7707315)
21. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
Yevich JP; New JS; Smith DW; Lobeck WG; Catt JD; Minielli JL; Eison MS; Taylor DP; Riblet LA; Temple DL
J Med Chem; 1986 Mar; 29(3):359-69. PubMed ID: 2869146
[TBL] [Abstract][Full Text] [Related]
24. Survey on the pharmacodynamics of the new antipsychotic risperidone.
Megens AA; Awouters FH; Schotte A; Meert TF; Dugovic C; Niemegeers CJ; Leysen JE
Psychopharmacology (Berl); 1994 Feb; 114(1):9-23. PubMed ID: 7531353
[TBL] [Abstract][Full Text] [Related]
25. Selective, centrally acting serotonin 5-HT2 antagonists. 1. 2- and 6-substituted 1-phenyl-3-(4-piperidinyl)-1H-indoles.
Perregaard J; Andersen K; Hyttel J; Sánchez C
J Med Chem; 1992 Dec; 35(26):4813-22. PubMed ID: 1336053
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and neuroleptic activity of 3-(1-substituted-4-piperidinyl)-1,2-benzisoxazoles.
Strupczewski JT; Allen RC; Gardner BA; Schmid BL; Stache U; Glamkowski EJ; Jones MC; Ellis DB; Huger FP; Dunn RW
J Med Chem; 1985 Jun; 28(6):761-9. PubMed ID: 2861286
[TBL] [Abstract][Full Text] [Related]
27. A study of the structure-affinity relationship in SYA16263; is a D
Onyameh EK; Bricker BA; Eyunni SVK; Voshavar C; Gonela UM; Ofori E; Jenkins A; Ablordeppey SY
Bioorg Med Chem; 2021 Jan; 30():115943. PubMed ID: 33338898
[TBL] [Abstract][Full Text] [Related]
28. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
[TBL] [Abstract][Full Text] [Related]
29. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
[TBL] [Abstract][Full Text] [Related]
30. New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.
Liao Y; Venhuis BJ; Rodenhuis N; Timmerman W; Wikström H; Meier E; Bartoszyk GD; Böttcher H; Seyfried CA; Sundell S
J Med Chem; 1999 Jun; 42(12):2235-44. PubMed ID: 10377229
[TBL] [Abstract][Full Text] [Related]
31. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
[TBL] [Abstract][Full Text] [Related]
32. Neuropharmacological profile of an atypical antipsychotic, NRA0562.
Hirota S; Kawashima N; Chaki S; Okuyama S
CNS Drug Rev; 2003; 9(4):375-88. PubMed ID: 14647530
[TBL] [Abstract][Full Text] [Related]
33. QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine.
Brea J; Castro M; Loza MI; Masaguer CF; Raviña E; Dezi C; Pastor M; Sanz F; Cabrero-Castel A; Galán-Rodríguez B; Fernández-Espejo E; Maldonado R; Robledo P
Neuropharmacology; 2006 Aug; 51(2):251-62. PubMed ID: 16697427
[TBL] [Abstract][Full Text] [Related]
34. Mixed D2/5-HT2 antagonism differentially affects apomorphine- and amphetamine-induced stereotyped behavior.
Feldman DJ; Frank RA; Kehne JH; Flannery R; Brown D; Soni S; Byrd G; Shah S
Pharmacol Biochem Behav; 1997 Oct; 58(2):565-72. PubMed ID: 9300620
[TBL] [Abstract][Full Text] [Related]
35. Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles.
Perregaard J; Arnt J; Bøgesø KP; Hyttel J; Sánchez C
J Med Chem; 1992 Mar; 35(6):1092-101. PubMed ID: 1348090
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and atypical antipsychotic profile of some 2-(2-piperidinoethyl)benzocycloalkanones as analogues of butyrophenone.
Fontenla JA; Osuna J; Rosa E; Castro ME; G-Ferreiro T; Loza-García I; Calleja JM; Sanz F; Rodríguez J; Raviña E
J Med Chem; 1994 Aug; 37(16):2564-73. PubMed ID: 7914540
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and structure-activity relationships of 4-amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist.
Hirokawa Y; Harada H; Yoshikawa T; Yoshida N; Kato S
Chem Pharm Bull (Tokyo); 2002 Jul; 50(7):941-59. PubMed ID: 12130853
[TBL] [Abstract][Full Text] [Related]
38. Analogues of the potential antipsychotic agent 1192U90: amide modifications.
Navas F; Tang FL; Schaller LT; Norman MH
Bioorg Med Chem; 1998 Jun; 6(6):811-23. PubMed ID: 9681147
[TBL] [Abstract][Full Text] [Related]
39. N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.
Birch AM; Bradley PA; Gill JC; Kerrigan F; Needham PL
J Med Chem; 1999 Aug; 42(17):3342-55. PubMed ID: 10464021
[TBL] [Abstract][Full Text] [Related]
40. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
